{"id":71835,"date":"2026-08-06T14:39:33","date_gmt":"2026-08-06T06:39:33","guid":{"rendered":"https:\/\/flcube.com\/?p=71835"},"modified":"2026-08-06T14:39:34","modified_gmt":"2026-08-06T06:39:34","slug":"eli-lilly-reports-record-q2-2026-revenue-of-22-97b-driven-by-tirzepatide-blockbusters-and-raises-full-year-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71835","title":{"rendered":"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced <strong>second-quarter 2026 financial results<\/strong> featuring <strong>revenue of USD 22.974 billion<\/strong>, representing a <strong>48% year-over-year increase<\/strong>. The exceptional performance was primarily driven by a <strong>60% increase in product volume<\/strong>, partially offset by a <strong>13% decrease in realized prices<\/strong>. The company&#8217;s <strong>Key Products revenue surged to USD 15.70 billion<\/strong>, led by <strong>tirzepatide franchise products Mounjaro and Zepbound<\/strong>, prompting Lilly to raise its <strong>full-year 2026 revenue guidance to USD 85.0\u201387.0 billion<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financial-highlights-q2-2026\" class=\"wp-block-heading\">Financial Highlights | Q2 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q2 2026 Result<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>USD 22.974 billion<\/td><td>+48%<\/td><\/tr><tr><td><strong>Key Products Revenue<\/strong><\/td><td>USD 15.70 billion<\/td><td>+121%<\/td><\/tr><tr><td><strong>U.S. Revenue<\/strong><\/td><td>USD 14.4 billion<\/td><td>+33%<\/td><\/tr><tr><td><strong>International Revenue<\/strong><\/td><td>USD 8.60 billion<\/td><td>+80%<\/td><\/tr><tr><td><strong>Mounjaro Sales<\/strong><\/td><td>USD 9.90 billion<\/td><td>+91%<\/td><\/tr><tr><td><strong>Zepbound U.S. Sales<\/strong><\/td><td>USD 4.9 billion<\/td><td>+44%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-therapeutic-area-performance\" class=\"wp-block-heading\">Therapeutic Area Performance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunology, Oncology &amp; Neuroscience<\/strong>: Key Products revenue grew <strong>121% year-over-year<\/strong>, demonstrating exceptional momentum across Lilly&#8217;s diversified portfolio<\/li>\n\n\n\n<li><strong>Diabetes &amp; Obesity<\/strong>: Dominated by tirzepatide franchise, with <strong>Mounjaro and Zepbound<\/strong> driving unprecedented volume growth globally<\/li>\n\n\n\n<li><strong>Cardiovascular<\/strong>: <strong>Jardiance<\/strong> contributed significantly to international revenue, including a <strong>USD 250 million sales-based milestone payment<\/strong> from the Boehringer Ingelheim collaboration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-geographic-revenue-analysis\" class=\"wp-block-heading\">Geographic Revenue Analysis<\/h2>\n\n\n\n<h3 id=\"h-united-states\" class=\"wp-block-heading\">United States<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue<\/strong>: USD 14.4 billion (+33% YoY)<\/li>\n\n\n\n<li><strong>Volume Growth<\/strong>: +37%, primarily driven by <strong>Zepbound and Mounjaro<\/strong><\/li>\n\n\n\n<li><strong>Price Impact<\/strong>: -3% decrease in realized prices, mainly attributed to <strong>Zepbound and Mounjaro<\/strong>, partially offset by rebate and discount adjustments for <strong>Trulicity, Zepbound, and Mounjaro<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-international-markets\" class=\"wp-block-heading\">International Markets<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue<\/strong>: USD 8.60 billion (+80% YoY)<\/li>\n\n\n\n<li><strong>Volume Growth<\/strong>: +113%, led by <strong>Mounjaro<\/strong><\/li>\n\n\n\n<li><strong>Price Impact<\/strong>: -36% decrease in realized prices, primarily due to <strong>Mounjaro&#8217;s inclusion in China&#8217;s National Reimbursement Drug List (NRDL)<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-product-specific-performance\" class=\"wp-block-heading\">Product-Specific Performance<\/h2>\n\n\n\n<h3 id=\"h-mounjaro-tirzepatide\" class=\"wp-block-heading\">Mounjaro (tirzepatide)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Sales<\/strong>: USD 9.90 billion (+91% YoY)<\/li>\n\n\n\n<li><strong>U.S. Sales<\/strong>: USD 4.80 billion (+45% YoY), reflecting strong demand partially offset by lower realized prices<\/li>\n\n\n\n<li><strong>International Sales<\/strong>: USD 5.20 billion (+172% YoY), driven primarily by volume growth<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-zepbound-tirzepatide\" class=\"wp-block-heading\">Zepbound (tirzepatide)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Sales<\/strong>: USD 4.9 billion (+44% YoY), primarily driven by strong demand, partially offset by lower realized prices<\/li>\n\n\n\n<li><strong>International Launch<\/strong>: Limited availability outside U.S. during Q2 2026<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-updated-full-year-2026-guidance\" class=\"wp-block-heading\">Updated Full-Year 2026 Guidance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Updated Guidance<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>USD 85.0\u201387.0 billion<\/td><\/tr><tr><td><strong>Performance Margin<\/strong><\/td><td>49.0%\u201350.5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The raised guidance reflects <strong>exceptional demand for tirzepatide products<\/strong>, successful commercial execution, and continued momentum across Lilly&#8217;s diversified therapeutic portfolio.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tirzepatide Dominance<\/strong>: The combined <strong>Mounjaro and Zepbound franchise<\/strong> generated nearly <strong>USD 15 billion in Q2 revenue<\/strong>, establishing Lilly as the dominant player in the GLP-1\/GIP dual agonist market<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Strategic price reductions, particularly through China&#8217;s NRDL inclusion, are driving massive volume adoption while maintaining strong overall profitability<\/li>\n\n\n\n<li><strong>Manufacturing Scale<\/strong>: Unprecedented volume growth demonstrates Lilly&#8217;s successful scaling of tirzepatide manufacturing capacity to meet global demand<\/li>\n\n\n\n<li><strong>Pipeline Validation<\/strong>: Strong commercial performance provides financial flexibility to invest in next-generation obesity and diabetes candidates<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, product sales, and business outlook. Actual results may differ materially due to competitive pressures, regulatory developments, manufacturing constraints, pricing pressures, and macroeconomic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Lilly-reports-second-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-continued-growth-and-pipeline-progress.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress.\"><\/object><a id=\"wp-block-file--media-ab84c17d-2369-4660-8e8a-adecb77387ef\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Lilly-reports-second-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-continued-growth-and-pipeline-progress.pdf\">Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Lilly-reports-second-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-continued-growth-and-pipeline-progress.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ab84c17d-2369-4660-8e8a-adecb77387ef\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71837,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[199,27,911],"class_list":["post-71835","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-eli-lilly","tag-finanical-reports","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD 22.974 billion, representing a 48% year-over-year increase. The exceptional performance was primarily driven by a 60% increase in product volume, partially offset by a 13% decrease in realized prices. The company&#039;s Key Products revenue surged to USD 15.70 billion, led by tirzepatide franchise products Mounjaro and Zepbound, prompting Lilly to raise its full-year 2026 revenue guidance to USD 85.0\u201387.0 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71835\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD 22.974 billion, representing a 48% year-over-year increase. The exceptional performance was primarily driven by a 60% increase in product volume, partially offset by a 13% decrease in realized prices. The company&#039;s Key Products revenue surged to USD 15.70 billion, led by tirzepatide franchise products Mounjaro and Zepbound, prompting Lilly to raise its full-year 2026 revenue guidance to USD 85.0\u201387.0 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71835\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-06T06:39:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-06T06:39:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance\",\"datePublished\":\"2026-08-06T06:39:33+00:00\",\"dateModified\":\"2026-08-06T06:39:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835\"},\"wordCount\":483,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0602.webp\",\"keywords\":[\"Eli Lilly\",\"Finanical Reports\",\"NYSE: LLY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71835#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71835\",\"name\":\"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0602.webp\",\"datePublished\":\"2026-08-06T06:39:33+00:00\",\"dateModified\":\"2026-08-06T06:39:34+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD 22.974 billion, representing a 48% year-over-year increase. The exceptional performance was primarily driven by a 60% increase in product volume, partially offset by a 13% decrease in realized prices. The company's Key Products revenue surged to USD 15.70 billion, led by tirzepatide franchise products Mounjaro and Zepbound, prompting Lilly to raise its full-year 2026 revenue guidance to USD 85.0\u201387.0 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71835\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71835#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD 22.974 billion, representing a 48% year-over-year increase. The exceptional performance was primarily driven by a 60% increase in product volume, partially offset by a 13% decrease in realized prices. The company's Key Products revenue surged to USD 15.70 billion, led by tirzepatide franchise products Mounjaro and Zepbound, prompting Lilly to raise its full-year 2026 revenue guidance to USD 85.0\u201387.0 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71835","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance","og_description":"Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD 22.974 billion, representing a 48% year-over-year increase. The exceptional performance was primarily driven by a 60% increase in product volume, partially offset by a 13% decrease in realized prices. The company's Key Products revenue surged to USD 15.70 billion, led by tirzepatide franchise products Mounjaro and Zepbound, prompting Lilly to raise its full-year 2026 revenue guidance to USD 85.0\u201387.0 billion.","og_url":"https:\/\/flcube.com\/?p=71835","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-06T06:39:33+00:00","article_modified_time":"2026-08-06T06:39:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71835#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71835"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance","datePublished":"2026-08-06T06:39:33+00:00","dateModified":"2026-08-06T06:39:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71835"},"wordCount":483,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71835#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0602.webp","keywords":["Eli Lilly","Finanical Reports","NYSE: LLY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71835#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71835","url":"https:\/\/flcube.com\/?p=71835","name":"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71835#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71835#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0602.webp","datePublished":"2026-08-06T06:39:33+00:00","dateModified":"2026-08-06T06:39:34+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD 22.974 billion, representing a 48% year-over-year increase. The exceptional performance was primarily driven by a 60% increase in product volume, partially offset by a 13% decrease in realized prices. The company's Key Products revenue surged to USD 15.70 billion, led by tirzepatide franchise products Mounjaro and Zepbound, prompting Lilly to raise its full-year 2026 revenue guidance to USD 85.0\u201387.0 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71835#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71835"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71835#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0602.webp","width":1080,"height":608,"caption":"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71835#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71835"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71835\/revisions"}],"predecessor-version":[{"id":71838,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71835\/revisions\/71838"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71837"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}